Gazyva (obinutuzumab) / Nippon Shinyaku, Biogen, Roche 
Welcome,         Profile    Billing    Logout  

210 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
2017-003593-13: UK CLL Long Term Follow Up Study

Ongoing
4
800
Europe
Obinutuzumab, Fludarabine, Fludarabine (IV), Cyclophospamide (oral), Cyclophosphamide (IV), Rituximab, Bendamustine, Mitoxantrone, Alemtuzumab, Ofatumumab, Concentrate for solution for infusion, Film-coated tablet, Powder for solution for infusion, Tablet, Powder for concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Obinutuzumab, Fludarabine (oral), Ofatumumab
University of Leeds, Napp Pharmaceuticals
Chronic lymphocytic leukaemia (CLL), Chronic lymphocytic leukaemia (CLL), Diseases [C] - Cancer [C04]
 
 
GAZELLE, NCT03817853: An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Completed
4
114
Europe, Japan, US, RoW
Obinutuzumab, GA101, RO5072759, Bendamustine, Cyclophosphamide, Doxorubicin, Prednisone/Prednisolone/Methylprednisolone, Vincristine
Hoffmann-La Roche
Advanced Follicular Lymphoma
08/20
01/23
2018-003255-38: A Study of Gazyva Short Duration Infusion (SDI) in Patients with Previously Untreated Follicular Lymphoma

Not yet recruiting
4
112
Europe
Obinutuzumab, RO5072759, Concentrate for solution for infusion, Gazyvaro
F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Follicular lymphoma, Follicular lymphoma (FL) is one of the most common common B cell-indolent non-Hodgkin's lymphomas (NHL) [type of blood cell cancer of the immune system], Diseases [C] - Cancer [C04]
 
 
ChiCTR2200062052: Canceled by the investigator. Observational study of tislelizumab combined with zanubrutinib, lenalidomide, obinutuzumab, methotrexate, and temozolomide in the treatment of diffuse large B-cell lymphoma with secondary CNS involvement

Not yet recruiting
4
20
 
None
The First Affiliated Hospital of Fujian Medical University ; The First Affiliated Hospital of Fujian Medical University, Beijing Ronghe Medical Development Foundation
diffuse large B-cell lymphoma with secondary CNS involvement
 
 
2020-005835-60: Treatment of lupus nephropathy without the addition of oral corticosteroids: a study comparing conventional corticosteroid and Mycophenolate Mofetil (MMF) therapy with Obinutuzumab and MMF Traitement des néphropathies lupiques sans adjonction de corticoïdes par voie orale: étude comparant un traitement classique par corticoïdes et Mycophénolate Mofétil (MMF) à un traitement par l’Obinutuzumab et le MMF

Not yet recruiting
3
196
Europe
Obinutuzumab, PREDNISONE, Mycophenolate mofetil, Azathioprine, RO5072759, Concentrate for solution for infusion, Tablet, , Gazyvaro
Assistance Publique – Hôpitaux de Paris (AP-HP), ministère de la santé, Roche
The study population will consist of Children (14 years and above) and adults (until 75 years old) with lupus nephritis ISN/RPS class III or IV (A or A/C) ± V with active lesions in at least 10% of the viable glomeruli, AND urine protein-to-creatinine ratio (uPCR) ≥ 0.5 g/g. La population étudiée sera composée d'enfants (à partir de 14 ans) et d'adultes (jusqu'à 75 ans) présentant un lupus néphrétique ISN/RPS de classe III ou IV (A ou A/C) ± V avec des lésions actives dans au moins 10 % des glomérules viables, ET un rapport protéines/créatinine urinaire (uPCR) ≥ 0,5 g/g., Children (14 years and above) and adults (until 75 years old) with lupus nephritis Enfants (à partir de 14 ans) et adultes (jusqu'à 75 ans) atteints de lupus néphrétique, Body processes [G] - Immune system processes [G12]
 
 
2022-000369-42: A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus Mycophenolate Mofetil (MMF) in Patients with Childhood Onset Idiopathic Nephrotic Syndrome

Ongoing
3
80
Europe
Obinutuzumab, mycophenolate mofetil, RO5072759, Concentrate for solution for infusion, Film-coated tablet, Powder for oral suspension, Gazyvaro, Cellcept
F. Hoffman-La Roche Ltd., F. Hoffman-La Roche Ltd, F. Hoffman-La Roche Ltd., F. Hoffman-La Roche Ltd
Childhood Onset Idiopathic Nephrotic Syndrome, Nephrotic syndrome is a kidney disorder that causes swelling in your body (especially in the face, legs and feet) and changes in your urine (too much protein)., Diseases [C] - Immune System Diseases [C20]
 
 
CLL14 study, NCT02242942 / 2014-001810-24: Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Checkmark 4 year data from trial in combination with obinutuzumab for previously untreated CLL at ASH 2020
Dec 2020 - Dec 2020: 4 year data from trial in combination with obinutuzumab for previously untreated CLL at ASH 2020
Checkmark From CLL-14 trial in combination with Gazyva in CLL
Sep 2020 - Sep 2020: From CLL-14 trial in combination with Gazyva in CLL
Checkmark From CLL-14 trial in combination with Gazyva in CLL at ASCO 2020
More
Active, not recruiting
3
445
Europe, Canada, US, RoW
Chlorambucil, Venetoclax, ABT-0199, GDC-0199, Obinutuzumab, GA-101; Gazyva
Hoffmann-La Roche, AbbVie, German CLL Study Group
Lymphocytic Leukemia, Chronic
08/18
08/25
ELEVATE-TN, NCT02475681 / 2014-005582-73: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

Hourglass Dec 2023 - Dec 2023 : Data from ELEVATE-TN in treatment-naive chronic lymphocytic leukemia at ASH 2023
Checkmark Presentation of data from ELEVATE TN trial in combination with obinutuzumab for 1L CLL at ASCO 2022
Jun 2022 - Jun 2022: Presentation of data from ELEVATE TN trial in combination with obinutuzumab for 1L CLL at ASCO 2022
Checkmark 5-year PFS data from ELEVATE CLL TN trial for CLL at ASCO 2022
Jun 2022 - Jun 2022: 5-year PFS data from ELEVATE CLL TN trial for CLL at ASCO 2022
More
Active, not recruiting
3
535
Europe, Canada, US, RoW
Acalabrutinib, ACP-196 (Calquence), Obinutuzumab, GAZYVA / GAZYVARO, Chlorambucil, LEUKERAN
Acerta Pharma BV
Chronic Lymphocytic Leukemia
02/19
09/25
2018-002443-28: This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with already marketed drugs called Venetoclax and Obinutzumab in comparison to chemotherapy that is already in wide use for treatment of patients who have chronic lymphocytic leukemia and who have never been treated before.

Not yet recruiting
3
780
Europe, RoW
acalabrutinib, ACP-196, Capsule, hard, Concentrate for solution for infusion, Powder for solution for injection/infusion, Concentrate for solution for injection/infusion, Film-coated tablet, Powder for concentrate for solution for infusion, Gazyvaro, MABTHERA, Venclyxto
Acerta Pharma B.V., ACERTA PHARMA BV, AstraZeneca, Acerta Pharma B.V., AstraZeneca AB, ASTRAZENECA AB, Acerta BV
Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation, Previously untreated low-risk blood cancer, Diseases [C] - Cancer [C04]
 
 
2019-003327-37: A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) without DEL (17P) or TP53 mutation Estudio para comparar la eficacia y seguridad de un régimen combinado de Venetoclax y Obinutuzumab versus fludarabina, ciclofosfamida y rituximab (FCR) / bendamustina y rituximab (BR) en pacientes FIT con leucemia linfocítica crónica (CLL) sin tratamiento previo sin DEL (17P) o mutación TP53

Not yet recruiting
3
165
Europe
Venclexta®, Venclyxto® or GDC-0199, Obinutuzumab, MabThera, Bendamustine, Cyclophosphamide, Fludarabine, Venclexta®, Venclyxto® or GDC- 0199, RO5537382, RO5072759, RO0452294, Film-coated tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Powder for solution for injection/infusion, Venclyxto® 10 mg film-coated tablets, Gazyvaro, MabThera 500 mg concentrate for solution for infusion, Venclyxto® 50 mg film-coated tablets, Venclyxto® 100 mg film-coated tablets
F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd
Chronic Lymphocytic Leukemia (CLL) Leucemia Linfocítica Crónica (LLC), CLL is a type of a cancer in which the bone marrow (BM) makes too many lymphocytes (a type of white blood cell) LLC es un tipo de cáncer en el cual la médula ósea (MO) produce demasiados linfocitos (un tipo de glóbulo blanco), Diseases [C] - Cancer [C04]
 
 
GLOW, NCT03462719 / 2017-004699-77: A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Checkmark New data from the P3 GLOW study in combination with ibrutinib in 1L CLL/SLL at ASH 2022
Dec 2022 - Dec 2022: New data from the P3 GLOW study in combination with ibrutinib in 1L CLL/SLL at ASH 2022
Checkmark Data from GLOW trial in combination with Venclexta for CLL at ASH 2021
Dec 2021 - Dec 2021: Data from GLOW trial in combination with Venclexta for CLL at ASH 2021
Checkmark Presentation of data from GLOW trial in combination with Venclexta for CLL/SLL at EHA 2021
More
Active, not recruiting
3
211
Europe, Canada, US, RoW
Ibrutinib, Venetoclax, Chlorambucil, Obinutuzumab, Ibrutinib (as Subsequent Therapy)
Janssen Research & Development, LLC, Pharmacyclics LLC.
Leukemia, Lymphocytic, Chronic, B-Cell
02/21
04/27
2020-003233-38: A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy

Not yet recruiting
3
140
Europe
Obinutuzumab, Tacrolimus, RO5072759, RO0485337, Concentrate for solution for infusion, Capsule, hard, Gazyvaro
F.Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd
Primary Membranous Nephropathy (pMN), pMN is a kidney-specific, autoimmune glomerular disease that presents with increased protein in the urine associated with an injury in glomeruli, Diseases [C] - Immune System Diseases [C20]
 
 
NCT02035462 / 2009-012476-28: CLL11: A Study of RO5072759 (GA101) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Active, not recruiting
3
787
US, Canada, Europe, RoW
RO5072759, rituximab, chlorambucil
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd., , F.Hoffmann-La Roche Ltd.
Lymphocytic Leukemia, Chronic
06/21
06/21
2020-004360-26: Comparison of a fixed-duration treatment of acalabrutinib, venetoclax and obinutuzumab to a treatment of venetoclax and obinutuzumab in patients with high risk chronic lymphocytic leukemia Vergleich einer befristeten Therapie mit Acalabrutinib, Venetoclax und Obinutuzumab mit der Therapie von Venetoclax und Obinutuzumab bei Patienten mit chronischer lymphytischer Leukämie mit hohem Risiko

Not yet recruiting
3
178
Europe
Acalabrutinib, Obinutuzumab, Venetoclax, RO5072759, Capsule, hard, Concentrate for solution for infusion, Film-coated tablet, Calquence, Gazyvaro®, Venclyxto
German CLL Study Group (University of Cologne), AstraZeneca
Patients with previously untreated chronic lymphocytic leukemia with treatment requiring disease and at least one out of three risk factors (17p-deletion, TP53 mutation or Complex karyotype)., Patients with chronic lymphocytic leukaemia (blood cancer) in need of firstline treatment and at least one out of three risk factors., Diseases [C] - Cancer [C04]
 
 
2020-003277-22: Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with Follicular Lymphoma Immunochemioterapia standard vs immunoterapia standard e chemioterapia a ridotto numero di cicli per il trattamento in prima linea di pazienti con Linfoma Follicolare

Not yet recruiting
3
602
Europe
Ciclofosfamide, Rituximab, Bendamustina, Doxorubicina, Prednisone, Vincristina, Obinutuzumab, [IMP4], [IMP1], [IMP3], [IMP2], [IMP5], [IMP8], [IMP7], [IMP6], , Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Concentrate for solution for injection/infusion, Concentrate and solvent for solution for infusion, Tablet, Solution for injection, ENDOXAN BAXTER - 200 MG POLVERE PER SOLUZIONE INIETTABILE 10 FLACONI VETRO TIPO III 200 MG, MABTHERA - 1 FIALA 500 MG 50 ML, LEVACT - 2.5 MG/ML POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE 5 FLACONCINI IN VETRO DA 100 MG, MABTHERA - 1400 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) 15 ML (120MG/ML) - 1 FLACONCINO, DOXORUBICINA TEVA - 2 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 10MG/5ML, PREDNISONE DOC GENERICI - "25 MG COMPRESSE" 10 COMPRESSE IN BLISTER PVC-PVDC/ALU, VINCRISTINA TEVA ITALIA - 1 MG/ML SOLUZIONE INIETTABILE 1 FLACONCINO DI VETRO DA 5 ML, GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO
FONDAZIONE ITALIANA LINFOMI ONLUS, FONDAZIONE GRADE ONLUS
High tumor burden Follicular Lymphoma Linfoma Follicolare ad elevato carico tumorale., High tumor burden Follicular Lymphoma. Linfoma Follicolare ad elevato carico tumorale., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT03406156: A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Completed
3
120
US
Obinutuzumab, Gazyva, Bendamustine, Bendeka, Venetoclax, Venclexta, ABT-199, GDC-0199
AbbVie
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
10/21
07/23
2021-000362-15: Therapy of follicular lymphoma with radiotherapy an antibody

Not yet recruiting
3
130
Europe
Concentrate for solution for infusion, GAZYVARO, MabThera
Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial, Roche Pharma AG, Department of Radiation Oncology, Universityhospital Heidelberg
nodal follicular lymphoma grade 1 or grade 2 in the clinical stage I or II (Ann Arbor classification), nodal follicular lymphoma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
UNITY-CLL, NCT02612311 / 2015-005758-36: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Checkmark Withdrawn sNDA filing in combination with ublituximab for adult patients with CLL and SLL
Apr 2022 - Apr 2022: Withdrawn sNDA filing in combination with ublituximab for adult patients with CLL and SLL
Checkmark From UNITY-CLL trial in combination with ublituximab for r/r CLL at ASH 2021
Dec 2021 - Dec 2021: From UNITY-CLL trial in combination with ublituximab for r/r CLL at ASH 2021
Checkmark From UNITY-CLL trial in combination with ublituximab for r/r CLL at iwCLL 2021
More
Terminated
3
603
Europe, US, RoW
Obinutuzumab, GAZYVA, Ublituximab, TGR-1202, Chlorambucil, Leukeran
TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia
02/23
02/23
EPCORE FL-2, NCT06191744: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Recruiting
3
1080
Europe, US, RoW
Epcoritamab, ABBV-GMAB-3013, GEN3013, Epkinly, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Genmab, AbbVie
Follicular Lymphoma (FL)
05/37
05/37
GAIA, NCT02950051 / 2015-004936-36: Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Hourglass Jan 2021 - Dec 2021 : From CLL13 trial in combination with Venclexta for 1L CLL
Completed
3
926
Europe, RoW
Fludarabine, Fludura, Cyclophosphamide, Endoxan, Rituximab, MabThera, Rituxan, Bendamustine, Ribomustin, Levact, Venetoclax, Venclexta, Venclyxto, Obinutuzumab, Gazyva, Gazyvaro, Ibrutinib, Imbruvica
German CLL Study Group, Janssen-Cilag Ltd., Hoffmann-La Roche, AbbVie, Stichting Hemato-Oncologie voor Volwassenen Nederland, Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research, Cancer Trials Ireland, Israeli CLL Study Group
Chronic Lymphocytic Leukemia
02/24
02/24
CRISTALLO, NCT04285567: A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Active, not recruiting
3
166
Europe, US, RoW
Obinutuzumab, Gazyva, RO5072759, GA101, Venetoclax, Venclexta, RO5537382, GDC-0199, Fludarabine, Cyclophosphamide, Rituximab, MabThera, Rituxan, Bendamustine, Treanda, Levact, Ribomustin
Hoffmann-La Roche
Chronic Lymphocytic Leukemia (CLL)
03/24
07/26
MorningLyte, NCT06284122: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Recruiting
3
790
Europe
Mosunetuzumab, Lenalidomide, Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristin, Prednisone, Bendamustin
The Lymphoma Academic Research Organisation, Lymphoma Study Association, Swiss Group for Clinical Cancer Research, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Follicular Lymphoma
11/28
04/34
NCT06428019: A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Not yet recruiting
3
120
NA
Venetoclax, ABT-199, Acalabrutinib, Obinutuzumab
AbbVie
Chronic Lymphocytic Leukemia
10/26
10/26
REGENCY, NCT04221477 / 2019-004034-42: A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis

Hourglass Oct 2023 - Dec 2023 : From REGENCY trial for lupus nephritis
Active, not recruiting
3
252
Europe, US, RoW
Obinutuzumab, Gazyva, GA101, RO5072759, MMF, Prednisone, Placebo, Methylprednisolone, Acetaminophen, Diphenhydramine
Hoffmann-La Roche
Lupus Nephritis
08/24
02/29
NCT04629248: A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

Active, not recruiting
3
140
Europe, US, RoW
Obinutuzumab, Gazyva, Tacrolimus, Methylprednisolone, Acetaminophen, Diphenhydramine
Hoffmann-La Roche
Primary Membranous Nephropathy
12/25
12/27
STARGLO, NCT04408638 / 2020-001021-31: A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Calendar Jan 2023 - Dec 2024: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for r/r DLBCL
Calendar Jan 2023 - Dec 2024: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for r/r DLBCL
Feb 2023 - Dec 2023: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for 2L+ DLBCL
Recruiting
3
270
Europe, US, RoW
Obinutuzumab, Glofitamab, Rituxumab, Tocilizumab, Gemcitabine, Oxaliplatin
Hoffmann-La Roche
Diffuse Large B-cell Lymphoma
04/25
04/25
ALLEGORY, NCT04963296 / 2020-005760-57: A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

Recruiting
3
300
Europe, US, RoW
Obinutuzumab, Gazyva, GA101, RO5072759, Placebo, Acetaminophen/Paracetamol, Diphenhydramine hydrochloride, Methylprednisolone
Hoffmann-La Roche
Systemic Lupus Erythematosus
11/25
11/27
GLOBRYTE, NCT06084936: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Recruiting
3
182
Europe, Canada, US, RoW
Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide, Tocilizumab
Hoffmann-La Roche
Lymphoma
02/26
12/26
NCT05197192 / 2020-004360-26: A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

Recruiting
3
650
Europe
Obinutuzumab, Gazyva, Gazyvaro, Venetoclax, Venclexta, Venclyxto, Acalabrutinib, Calquence
German CLL Study Group, AstraZeneca
Chronic Lymphocytic Leukemia
05/26
02/27
INShore, NCT05627557 / 2022-000369-42: A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome

Recruiting
3
80
Europe, Japan, US, RoW
Obinutuzumab, MMF, Prednisone, Non-Investigational Medicinal Product, Methylprednisolone, Acetaminophen/ Paracetamol, Diphenhydramine Hydrochloride
Hoffmann-La Roche, F. Hoffman-La Roche Ltd., F. Hoffman-La Roche Ltd
Childhood Idiopathic Nephrotic Syndrome
08/26
08/26
FORTplus, NCT05045664: Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody

Recruiting
3
100
Europe
Standard, Experimental, Rituximab, Obinutuzumab
Heidelberg University
Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a
12/26
12/29
NCT05211856: Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Recruiting
3
780
Europe, Canada, US, RoW
Acalabrutinib, Calquence (acalabrutinib), Venetoclax, Venclyxto, Venclexta, Chemoimmunotherapy, Obinutuzumab, Gazyva, Gazyvaro
AstraZeneca
Chronic Lymphocytic Leukemia
01/27
01/27
ACE-CL-311, NCT03836261: Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Calendar Jan 2027 - Mar 2027: Last patient dosing of P3 ACE-CL-311 trial in combination with venetoclax for previously untreated CLL
Calendar Jan 2024 - Dec 2024: Data from AMPLIFY trial in combination with Calquence and obinutuzumab for previously untreated CLL
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with venclexta and obinutuzumab for 1L CLL (based on AMPLIFY trial)
Hourglass Jul 2022 - Dec 2022 : From P3 ACE-CL-311 trial in combination with Venclexta for 1L CLL
Active, not recruiting
3
984
Europe, Canada, US, RoW
Acalabrutinib, Calquence (acalabrutinib), Venetoclax, Venclyxto, Venclexta, Chemoimmunotherapy, Obinutuzumab, Gazyva, Gazyvaro
Acerta Pharma BV, AstraZeneca
Chronic Lymphocytic Leukemia
01/27
01/27
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting
3
897
Europe, RoW
Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro
German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG)
Chronic Lymphoid Leukemia
03/27
03/27
MAJIC, NCT05057494 / 2021-003936-10: A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active, not recruiting
3
607
Europe, US, RoW
Acalabrutinib, Venetoclax, Obinutuzumab
AstraZeneca
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
07/27
04/29
A041702, NCT03737981: Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Active, not recruiting
3
454
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Observation, Inspection, Visual Inspection, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/27
06/27
REMIT, NCT06120673: REmission in Membranous Nephropathy International Trial

Not yet recruiting
3
224
RoW
Obinutuzumab, Oral prednisolone and cyclophosphamide
The University of Queensland, University of Adelaide
Primary Membranous Nephropathy
01/28
01/28
NCT03701282: Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

Active, not recruiting
3
720
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/28
05/28
MAHOGANY, NCT05100862: A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Recruiting
3
750
Europe, US, RoW
Zanubrutinib, BGB-3111, Brukinsa, Rituximab, Rituxan, MabThera, Ruxience, Truxima, Lenalidomide, Revlimid, Obinutuzumab
BeiGene
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
07/28
06/30
EVOLVE CLL/SLL, NCT04269902: Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), Study

Recruiting
3
247
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
10/28
10/28
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting
3
190
Europe
Radiotherapy, Radiotherapy plus Obinutuzumab
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Follicular Lymphoma
04/31
04/31
OBILUP, NCT04702256 / 2020-005835-60: Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF

Recruiting
3
196
Europe
Obinutuzumab administration, GAZYVARO® administration, Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil, Corticosteroid Series, Administration of methylprednisolone, paracetamol and dexchlorpheniramine, Premedication
Assistance Publique - Hôpitaux de Paris, Roche Pharma AG
Lupus Nephritis, Systemic Lupus Erythematosus (SLE)
12/31
12/31
CELESTIAL-TNCLL, NCT06073821: Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

Recruiting
3
640
Europe, Canada, US, RoW
Sonrotoclax, BGB-11417, Zanubrutinib, BGB-3111, Venetoclax, Obinutuzumab
BeiGene
CLL
02/32
12/32
2014-000880-42: A phase II/III trial to assess the use of obinutuzmab against no treatment in patients who have recently had a good response to previous treatment for Chronic Lymphocytic Leukaemia (CLL)

Ongoing
2/3
188
Europe
Obinutuzumab, GA-101, Concentrate for solution for infusion, Gazyvaro
University of Leeds, Cancer Research UK/Clinical Trials Advisory and Awards Committee (CRUK/CTAAC), Roche Products Ltd
Chronic Lymphocytic Leukaemia (CLL)., Chronic Lymphocytic Leukaemia (CLL)., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
OBIRINS, NCT05786768: Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome

Recruiting
2/3
88
Europe
single infusion of Rituximab, single infusion of Rituximab 375 mg/m2, single infusion of Obinutuzumab, single infusion of Obinutuzumab 300mg/1.73 m2
Assistance Publique - Hôpitaux de Paris
Steroid-Dependent Nephrotic Syndrome, Steroid-Sensitive Nephrotic Syndrome
10/27
12/27
2013-004635-69: A phase II study of obinutuzumab monotherapy in rituximab-refractory follicular lymphoma Obinutuzumab monotherapie voor rituximab-refractair folliculair lymfoom

Ongoing
2
25
Europe
obinutuzumab, obinutuzumab-N-succinyl-desferal-zirconium-89, RO5072759, 89Zr-obinutuzumab, Concentrate for solution for infusion, Solution for injection/infusion
VU University Medical Center, VU University Medical Center, Roche Nederland B.V.
rituximab refractory follicular lymphoma, rituximab refractory follicular lymphoma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2015-005273-20: Multicenter phase II single arm open-label study on the feasibility, safety and efficacy of combination of CHOP-21 supplemented with Obinutuzumab and Ibrutinib in untreated young high risk Diffuse Large B-cell Lymphoma (DLBCL) patients. Studio multicentrico di fase II a braccio singolo sulla fattibilit¿, sicurezza ed efficacia della combinazione CHOP-21 con Obinutuzumab e Ibrutinib come terapia di prima linea in pazienti giovani ad alto rischio affetti da linfoma a grandi cellule B.

Not yet recruiting
2
90
Europe
Imbruvica, Ibrutinib, Concentrate for solution for infusion, Capsule, hard, GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO, IMBRUVICA - 140 MG -CAPSULE RIGIDE -USO ORALE - FLACONE (HDPE) - 1 FLACONE (90 CAPSULE RIGIDE)
FONDAZIONE ITALIANA LINFOMI ONLUS, Roche, Janssen - Cilag
Diffuse Large B-Cell lymphoma (DLBCL) Linfoma a grandi cellule B (DLBCL), Diffuse Large B-Cell lymphoma Linfoma a grandi cellule B, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2016-001033-27: REMODEL - WM3 An Open Label non-randomized Phase II Study exploring «chemo-free » treatment association with Idelalisib + Obinutuzumab in Patient with relapsed/refractory Waldenstrom’s Macroglobulinemia (MW) REMODEL - WM3 Etude ouverte de phase II évaluant l’efficacité d’un traitement «sans chimiothérapie » par l’association de l’Idelalisib avec l’Obinutuzumab chez les patients atteints de la Maladie de Waldenström (MW)

Ongoing
2
50
Europe
Obinutuzumab, R05072759/F06-01, Concentrate for solution for infusion, Film-coated tablet, Gazyvaro, Zydelig
FILO, Roche, GILEAD
Waldenstrom’s Macroglobulinemia (MW) Macroglobulinémie de Waldenstrom (MW), Patient with relapsed/refractory Waldenstrom’s Macroglobulinemia Patient en rechute ou réfractaire d'une macroglobulinémie de Waldenstrom, Diseases [C] - Cancer [C04]
 
 
2015-004985-27: A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens

Ongoing
2
70
Europe
obinutuzumab, venetoclax 10 mg, venetoclax 50mg, venetoclax 100mg, Concentrate for solution for infusion, Tablet, Gazyvaro
HOVON Foundation, Dutch Cancer Society, Roche
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04]
 
 
NCT02401503 / 2014-000580-40: Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

Checkmark In combination with obinutuzumab following bendamustine
Aug 2018 - Aug 2018: In combination with obinutuzumab following bendamustine
Active, not recruiting
2
66
Europe
Bendamustine, GA101, Obinutuzumab, ABT-199, Venetoclax, GDC-0199
German CLL Study Group, Hoffmann-La Roche, AbbVie
Chronic Lymphocytic Leucemia
12/16
12/24
2017-001836-20: STEP-WISE COMBINATION OF OBINUTUZUMAB, VEMURAFENIB AND COBIMETINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) PREVIOUSLY TREATED WITH PURINE ANALOGS OR UNFIT FOR CHEMOTHERAPY: A PHASE-2, SINGLE-ARMS, ITALIAN, MULTICENTER STUDY (HCL-PG04) COMBINAZIONE SEQUENZIALE DI OBINUTUZUMAB, VEMURAFENIB E COBIMETINIB IN PAZIENTI CON LEUCEMIA A CELLULE CAPELLUTE (HAIRY CELL LEUKEMIA – HCL) PRECEDENTEMENTE TRATTATI CON ANALOGHI DELLE PURINE O NON IDONEI ALLA CHEMIOTERAPIA: STUDIO ITALIANO DI FASE II, MULTICENTRICO, A SINGOLI BRACCI (HCL-PG04)

Ongoing
2
42
Europe
obinutuzumab, Vemurafenib, cobimetinib, -, Solution for infusion, Film-coated tablet, GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO, ZELBORAF - 240 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) 56 COMPRESSE
PROF.BRUNANGELO FALINI, DR.ENRICO TIACCI. DIPARTIMENTO DI MEDICINA, UNIVERSITA' DI PERUGIA, Fondi del Dip. Medicina e contributo Roche
HCL patients carrying the BRAF-V600E mutation pazienti con HCL positivi alla mutazione BRAF-V600E, patients with Hairy Cell Leukemia carrying the BRAF-V600E mutation pazienti affetti da Leucemia a Cellule Capellute positivi alla mutazione BRAF-V600E, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NOBILITY, NCT02550652 / 2015-002022-39: A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

Checkmark Efficacy and safety data from NOBILITY trial for lupus nephritis
Nov 2020 - Nov 2020: Efficacy and safety data from NOBILITY trial for lupus nephritis
Checkmark Safety and efficacy data from trial for lupus nephritis at ASN/ACR 2019
Nov 2019 - Nov 2019: Safety and efficacy data from trial for lupus nephritis at ASN/ACR 2019
Checkmark Safety and efficacy data from NOBILITY trial in lupus nephritis
More
Completed
2
126
Europe, US, RoW
Mycophenolate Mofetil/Mycophenolic Acid, Obinutuzumab, Gazyva, GA101, RO5072759, Placebo, Methylprednisolone, Prednisone
Hoffmann-La Roche
Lupus Nephritis
01/19
08/23
LYMA-101, NCT02896582 / 2016-000548-33: Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

Checkmark From LyMa-101 trial in combination with high-dose cytarabine induction in 1L mantle cell lymphoma
Sep 2020 - Sep 2020: From LyMa-101 trial in combination with high-dose cytarabine induction in 1L mantle cell lymphoma
Active, not recruiting
2
86
Europe
Obinutuzumab, GA, GA101, Dexamethasone, Aracytine, Cytarabine, Cisplatinum, Etoposide, Melphalan, Carmustine, BiCNU, BCNU
The Lymphoma Academic Research Organisation
Mantle Cell Lymphoma
03/19
03/25
OBI-1, NCT03679455 / 2016-005053-20: A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia,

Recruiting
2
30
Europe
Obinutuzumab 25 MG/ML, Gazyvaro
Polish Myeloma Consortium, Roche Pharma AG, Bioscience, S.A.
Waldenstrom Macroglobulinemia
04/19
12/22
2018-001229-18: Idelalisib (I) in combination with Obinutuzumab (G) for the treatment of patients with relapsed / refractory follicular lymphoma: multicentric phase II single arm study. Idelalisib (I) in combinazione con Obinutuzumab (G) per il trattamento di pazienti con linfoma follicolare ricaduto/refrattario: studio multicentrico di fase II a braccio singolo.

Not yet recruiting
2
43
Europe
Zydelig, GAZYVARO, [IMP1], [Obinutuzumab], Capsule, hard, Concentrate for solution for infusion, Zydelig, Gazyvaro
FONDAZIONE ITALIANA LINFOMI ONLUS, GILEAD, ROCHE
recurrent / refractory follicular lymphoma linfoma follicolare ricaduto/refrattario, recurrent / refractory follicular lymphoma linfoma follicolare ricaduto/refrattario, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2018-003270-27: Evaluation of a treatment with bendamustine, followed by obinutuzumab,zanubrutinib and venetoclax in patients with relapsed chronic lymphocyticleukemia

Not yet recruiting
2
40
Europe
Bendamustine, Obinutuzumab / GA101, ABT-199 (GDC-0199), Venetoclax, Zanubrutinib, RO5072759, BGB-3111, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tablet, Capsule, hard, Gazyvaro, Venclyxto (Venetoclax)
Universität zu Köln B.1.2, BeiGene Ltd., Roche Pharma AG
Patients with relapsed/refractory CLL requiring treatment, Patients with relapsed chronic lymphocytic leukaemia in need oftreatment, Diseases [C] - Cancer [C04]
 
 
2018-004038-13: Chemotherapy-free combination of Copanlisib withObinutuzumab (GA 101) in Patients with Previously Untreated FollicularLymphoma (FL) and High Tumor Burden

Not yet recruiting
2
102
Europe
Copanlisib, Obinutuzumab, BAY 80-6946, RO5072759/F06-01, Lyophilisate for solution for infusion, Concentrate for solution for infusion, Gazyvaro
Klinikum der Universität München, Bayer HealthCare Pharmaceuticals Inc., Roche Pharma AG
Follicular Lymphoma with high tumor burden (grade 1- 3a, Ann Arbour stage II - IV, previously untreated), Follicular Lymphoma with need of treatment, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
RemodelWM3, NCT02962401: Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia

Completed
2
50
Europe
Obinutuzumab, GA101, Idelalisib, Zydelig
French Innovative Leukemia Organisation
Waldenstrom Macroglobulinemia
08/20
04/23
CLL2-BAAG, NCT03787264 / 2017-003133-28: Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL

Completed
2
46
Europe
Bendamustine, Obinutuzumab, GA101, Gazyvaro, Acalabrutinib, ACP-196, Calquence, Venetoclax, ABT-199, Venclyxto
German CLL Study Group
Chronic Lymphoid Leukemia
02/21
09/23
GAUDEALIS, NCT03890289: Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma

Terminated
2
5
Europe
Idelalisib, Obinutuzumab
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
04/21
05/23
PrE0403, NCT03113422: Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

Completed
2
56
US
Induction Venetoclax, GDC-0199, ABT-199, RO5537382, Maintenance Venetoclax
PrECOG, LLC., Genentech, Inc.
Follicular Lymphoma, Non-Hodgkin's Lymphoma Follicular, Non-Hodgkin's Lymphoma, Adult High Grade
05/21
01/23
2021-000311-23: Ibrutinib and Obinutuzumab as first-line treatment for patients with Chronic Lymphocytic Leukemia Ibrutinib e Obinutuzumab come trattamento di prima linea per pazienti affetti dalla Leucemia Linfatica Cronica

Not yet recruiting
2
53
Europe
NA, Gazyvaro, [NA], [Gazyvaro], Capsule, hard, Concentrate for solution for injection, imbruvica, gazyvaro
OSPEDALE SAN RAFFAELE, Janssen-Cilag International N.V., Belgium
chronic lymphocytic leukemia/small lymphocytic lymphoma Leucemia Linfatica Cronica/ Linfoma linfocitico a piccole cellule, chronic lymphocytic leukemia/small lymphocytic lymphoma Leucemia Linfatica Cronica/ Linfoma linfocitico a piccole cellule, Diseases [C] - Cancer [C04]
 
 
2021-000097-29: A Phase II Randomized Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients with Active Class III or IV Lupus Nephritis Estudio fase II, aleatorizado y controlado paraevaluar la eficacia, seguridad y farmacocinética de obinutuzumab en pacientes adolescentes con nefritis lúpica de casle III o IV activa

Not yet recruiting
2
30
Europe
Obinutuzumab, mycophenolate mofetil, RO5072759, Concentrate for solution for infusion, Tablet, Gazyvaro, Myfenax
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. Hoffman-La Roche Ltd., F. HOFFMANN - LA ROCHE LTD., F. Hoffman-La Roche Ltd.
Lupus Nephritis (LN) Nefritis lúpica (NL), Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). SLE is an autoimmune disease, in which the body’s immune system attacks its own healthy body tissue. La nefritis lúpica es una inflamación del riñón causada por el lupus eritematoso sistémico(LES).LES es una enfermedad autoinmune,en la que el sistema inmune del cuerpo ataca sus propios tejidos sanos, Diseases [C] - Immune System Diseases [C20]
 
 
GAZAI, NCT03341520 / 2016-002059-89: Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma

Active, not recruiting
2
89
Europe
Obinutuzumab Injection [Gazyva], Gazyvaro, Low dose radiation Therapy (LDRT)
Heidelberg University, Roche Pharma AG
Stage II Grade 1 Follicular Lymphoma, Stage II Grade 2 Follicular Lymphoma, Stage I Follicular Lymphoma Grade 1, Stage II Follicular Lymphoma Grade 2
11/21
05/24
GABe2016, NCT03492775 / 2016-000755-27: First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years

Completed
2
46
Europe
Obinutuzumab, GA 101, Bendamustine, Bendamustine hydrochloride; Ribomustin
Prof. Dr. Wolfgang Hiddemann, Hoffmann-La Roche, Mundipharma Research GmbH & Co KG
Indolent Non-hodgkin Lymphoma
11/21
12/22
2021-004864-81: Proposta di studio per valutare l’efficacia di Obinutuzumab, un anticorpo anti-CD20, in pazienti con nefropatia membranosa intolleranti, resistenti o dipendenti alla terapia con Rituximab (studio ORION) OBINUTUZUMAB FOR PRIMARY MEMBRANOUS NEPHROPATHY: A PILOT STUDY IN PATIENTS WITH RITUXIMAB-RESISTANT OR RITUXIMAB-DEPENDENT NEPHROTIC SYNDROME AND IN PATIENTS INTOLERANT TO RITUXIMAB (THE ORION STUDY)

Not yet recruiting
2
20
Europe
GAZYVARO, OMNIPAQUE, [L01XC15], [Ioexolo], Concentrate and solvent for solution for infusion, Solution for injection, GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO, OMNIPAQUE - 300 MG I/ML SOLUZIONE INIETTABILE FLACONE IN POLIPROPILENE DA 50 ML
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, Roche, IRCCS Istituto Mario Negri
PRIMARY MEMBRANOUS NEPHROPATHY Nefropatia membranosa primaria, PRIMARY MEMBRANOUS NEPHROPATHY Nefropatia membranosa primaria, Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
 
 
CLL2-BCG, NCT02445131 / 2014-000582-47: Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL

Completed
2
48
Europe
Bendamustine, GA101, Obinutuzumab, CAL-101, Idelalisib
German CLL Study Group, Hoffmann-La Roche, Gilead Sciences
Chronic Lymphocytic Leucemia
03/22
03/22
2019-000914-12: Gazyvaro Targeting Tumor Promoting, Regulatory B-cells in Solid Tumors

Not yet recruiting
2
27
Europe
TECENTRIQ (atezolizumab), GAZYVA (Obinutuzumab/, Infusion, Injection, TECENTRIQ (atezolizumab), GAZYVA (Obinutuzumab)
University of Cologne, F. Hoffmann La Roche
• Melanoma: unresectable stage III with macroscopic lymph node, in transit/satellite metastasis or stage IV after ≥ 2 lines of therapy (incl. checkpoint blockade, BRAF inhibitor)• Prostate carcinoma: castration-resistant, 2 lines of chemotherapy failed• CTCL: ≥ stage IIB, ≥ 2 previous lines of treatment, Patients with late stage Melanoma, Prostate carcinoma or Cutaneous T cell lymphoma (CTCL), Diseases [C] - Cancer [C04]
 
 
NCT02689869 / 2014-005164-15: Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma

Active, not recruiting
2
98
Europe
Ibrutinib, Imbruvica, GA 101, Obinutuzumab
Ludwig-Maximilians - University of Munich, Hoffmann-La Roche, Janssen-Cilag G.m.b.H
Indolent Non-Hodgkin Lymphoma
04/22
07/22
ROSEWOOD, NCT03332017 / 2017-001552-54: A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

Active, not recruiting
2
217
Europe, Canada, US, RoW
Zanubrutinib, BGB-3111, Brukinsa, Obinutuzumab, Gazyva
BeiGene
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
10/21
10/24
Alternative-C, NCT05387616: A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden

Active, not recruiting
2
98
Europe
Copanlisib, ALIQOPA™, Obinutuzumab, GAZYVARO®
Ludwig-Maximilians - University of Munich, Roche Pharma AG, Bayer
Follicular Lymphoma
09/23
05/26
2022-002579-12: First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl-2 inhibitor with BTK inhibitor according to disease status of the young patient with high risk Chronic Lymphatic Leukemia Associazione di un inibitore di Bcl-2 e un anticorpo monoclonale in prima linea seguita dalla somministrazione del solo inibitore di Bcl-2 o dall'associazione dell'inibitore di Bcl-2 con un inibitore di BTK in base all'andamento della malattia del paziente giovane con Leucemia linfatica cronica ad alto rischio.

Not yet recruiting
2
78
Europe
Gazyvaro 1000 mg, Venclyxto 10 mg, Venclyxto 50 mg, Venclyxto 100 mg, Brukinsa, Bactrim, Lamivudina, Trimeton, Tachipirina, Decadron, Allopurinolo, [NA], [N.A.], Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Tablet, Concentrate for solution for injection, Solution for injection, Buccal tablet
FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, BeiGene, Roche, Fondazione GIMEMA Franco Mandelli Onlus
Chronic Lymphocytic Leukemia Leucemia linfatica cronica, Form of cancer characterized by the abnormal proliferation of a particular type of cells present in the blood (lymphocytes) with consequent accumulation in various parts of the body Forma di cancro caratterizzata dalla proliferazione abnorme di un particolare tipo di cellule presenti nel sangue (linfociti) con conseguente accumulo in varie parti del corpo, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2022-003398-51: A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dose R-CHOP Eine prospektive, multizentrische Phase-2-Studie zur chemotherapiearmen Kombination von Rituximab mit dem Antikörper-Wirkstoff-Konjugat Polatuzumab Vedotin und dem bispezifischen Antikörper Glofitamab bei zuvor unbehandelten Patienten mit aggressivem B-Zell-Lymphom über 60 Jahren, die für ein voll dosiertes R-CHOP nicht in Frage kommen

Not yet recruiting
2
80
Europe
Glofitamab, Obinutuzumab, Polatuzumab vedotin, Rituximab, RO7082859, RO5072759, RO5541077, RO0452294, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Columvi, GAZYVARO, Polivy, MabThera
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Roche Pharma AG, Roche Austria GmbH
aggressive large B-cell lymphoma, aggressive large B-cell lymphoma, Diseases [C] - Cancer [C04]
 
 
PALG ALL7, NCT04920968: Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/ OVERALL

Not yet recruiting
2
124
Europe
Obinutuzumab, Rituximab, Activ comparator
Maria Sklodowska-Curie Institute - Oncology Center, KCRI
CD20-positive Acute Lymphoblastic Leukemia
06/23
12/24
NCT03311126: Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Terminated
2
21
US
Bendamustine, Obinutuzumab, GA101, RO5072759
University of Wisconsin, Madison, Genentech, Inc.
Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma
07/23
07/23
NCT03872180: Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Active, not recruiting
2
23
US
Bendamustine, SDX-105, Obinutuzumab, GA-101, Gazyva, RO5072759, Venetoclax, ABT-199, GDC-0199, RG7601, Venclexta, RO5537382
Emory University, Genentech, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive
09/24
04/26
BiCAR, NCT04703686 / 2020-001985-12: Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Active, not recruiting
2
67
Europe
Obinutuzumab, gazyva, RO7082859, glofitamab
The Lymphoma Academic Research Organisation
Diffuse Large B-Cell Lymphoma Refractory, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma, Refractory Mantle Cell Lymphoma
01/23
03/26
NCT04450173: Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Recruiting
2
40
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Joseph Tuscano, National Cancer Institute (NCI), Pharmacyclics LLC., Genentech, Inc.
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
10/24
04/25
FLUORO, NCT04962126: Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy

Active, not recruiting
2
15
RoW
Obinutuzumab 25 MG/1 ML Intravenous Solution, Gazyva, Atezolizumab 1200 MG/40mL Intravenous Solution, Tecentriq, 4 Gy in 2 fractions
Olivia Newton-John Cancer Research Institute, Roche Products Pty Limited, Austin Health, Ballarat Health Services
Follicular Lymphoma
04/23
07/25
NCT02867384: Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

Active, not recruiting
2
181
US
Obinutuzumab, Gazyva, Placebo
Dana-Farber Cancer Institute, Roche-Genentech
Graft vs. Host Disease
11/23
10/24
NCT06415708: Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

Recruiting
2
134
RoW
Obinutuzumab Combined With Bendamustine
Institute of Hematology & Blood Diseases Hospital, China
B Cell Lymphoma
11/24
06/26
17P.176, NCT03198026: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Recruiting
2
30
US
Ibrutinib, 2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, 936563-96-1, Obinutuzumab, 949142-50-1, Anti-CD20 Monoclonal Antibody R7159, Gazyva, R7159, RO 5072759, GA-101, GA101, huMAB(CD20), RO-5072759, RO5072759, Laboratory Biomarker Analysis
Sidney Kimmel Cancer Center at Thomas Jefferson University, Genentech, Inc., Pharmacyclics LLC.
Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Nodal Marginal Zone Lymphoma, Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Nodal Marginal Zone Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Nodal Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-hodgkin Lymphoma, Stage II Splenic Marginal Zone Lymphoma, Stage III Splenic Marginal Zone Lymphoma, Stage IV Splenic Marginal Zone Lymphoma
12/24
02/31
NCT05510219: Safety Analysis of Intravenous Rapid Infusion of Obinutuzumab in Patients With B-cell Non-Hodgkin's Lymphoma in China

Recruiting
2
200
RoW
intravenous rapid infusion of obinutuzumab
The First Affiliated Hospital with Nanjing Medical University
Obinutuzumab, Rapid Infusion, Intravenous Infusion Reaction
12/23
12/23
NCT05823701: Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

Recruiting
2
23
RoW
Chidamide, Tucidinostat, Azacitidine, AZA, obinutuzumab, Gazyva, Liposomal mitoxantrone, PLM60
The First Affiliated Hospital of Soochow University
Diffuse Large B-Cell Lymphoma
12/23
12/25
NCT02498951: Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Terminated
2
32
US
Cognitive Assessment, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment
OHSU Knight Cancer Institute, Genentech, Inc., National Cancer Institute (NCI), Oregon Health and Science University, Providence Health & Services
Central Nervous System B-Cell Non-Hodgkin Lymphoma
03/24
03/24
NCT03410875: A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

Active, not recruiting
2
30
US
Vemurafenib, Obinutuzumab
Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Yale University
Hairy Cell Leukemia, Leukemia, Leukemia, Hairy Cell
01/25
01/25
NT-NAP-102-1, NCT04880863: Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC

Completed
2
38
US
NAP (Naptumomab estafenatox), ABR-217620, Anyara, Docetaxel, Taxotere, Obinutuzumab, Gazyva
NeoTX Therapeutics Ltd., Translational Drug Development
Non-small Cell Lung Cancer
01/24
01/24
NCT04883437: Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Recruiting
2
49
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Emory University, AstraZeneca, National Cancer Institute (NCI)
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-Hodgkin Lymphoma, Lymphoplasmacytic Lymphoma, Lymphoproliferative Disorder, Mantle Cell Lymphoma, Marginal Zone Lymphoma
01/24
01/24
NCT03401853: Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Active, not recruiting
2
18
US
Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, rituximab biosimilar TQB2303, rituximab-abbs, Truxima, Rituximab Biosimilar SIBP-02, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
University of Washington, Merck Sharp & Dohme LLC
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma
12/23
12/25
SA-002804, NCT04939363: A Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter's Syndrome;

Recruiting
2
15
RoW
Obinutuzumab with Ibrutinib and Venetoclax
Bnai Zion Medical Center, Tel-Aviv Sourasky Medical Center
Richter's Syndrome
03/24
09/24
NCT06175000: Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Recruiting
2
30
US
Cognitive Assessment, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB (CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality of Life Assessment
Providence Health & Services
Primary Central Nervous System Lymphoma
09/28
09/29
GLORIFY, NCT06186648: Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome

Recruiting
2
40
Europe
Glofitamab + Obinutuzumab
French Innovative Leukemia Organisation, Hoffmann-La Roche
Richter Syndrome
03/26
03/27
NCT03580928: Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

Hourglass Dec 2022 - Dec 2022 : Presentation of data from Phase 2 trial in combination with Venetoclax and Obinutuzumab for 1L CLL at ASH 2022
Active, not recruiting
2
72
US
Venetoclax, Venclexta, Obinutuzumab, Gazyva, Acalabrutinib, Calquence
Dana-Farber Cancer Institute, AstraZeneca, Genentech, Inc., National Institutes of Health (NIH), National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia (CLL)
04/24
12/27
NCT06333262: Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Recruiting
2
60
US
Pirtobrutinib, Obinutuzumab
Inhye Ahn, Loxo Oncology, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
02/27
02/29
NCT06324994: Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

Not yet recruiting
2
10
RoW
Linperlisib in combination with Obinutuzumab and Venetoclax, Treatment group
Dalian Medical University
Mantle Cell Lymphoma
05/25
12/26
NCI-2024-00209, NCT06213311: A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

Recruiting
2
40
US
Glofitamab, RO7082859, RG6026, Obinutuzumab, GA101, Gazyva, RO5072759, Axi-cel, Axicabtagene ciloleucel, KTE-C19, KTE-X19
M.D. Anderson Cancer Center, Genentech, Inc., Kite, A Gilead Company
B Cell Lymphoma
01/25
01/27
NCT06427213: This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma

Not yet recruiting
2
41
NA
Zanubrutinib,Obinutuzumab, Zanubrutinib and R-BAC
Henan Cancer Hospital
Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin
12/27
12/29
OLYMP-1, NCT03322865 / 2017-003149-56: Obinutuzumab in Marginal Zone Lymphoma

Active, not recruiting
2
56
Europe
Obinutuzumab, GA101
Christian Buske, University of Ulm, Optimapharm, Zentrum für Klinische Studien Ulm, X-act Cologne Clinical Research GmbH, Roche Pharma AG
Marginal Zone Lymphoma
06/24
11/28
NCT04505254: Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Recruiting
2
60
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/24
06/24
NCI-2024-00054, NCT06252675: Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Recruiting
2
50
US
Obinutuzumab, Anti-CD20 Monoclonal Antibody R715, huMAB(CD20), RO5072759, Glofitamab, Anti-CD3 Bispecific Monoclonal Antibody RO7082859, RO7082859, Pirtobrutinib, LOXO-305, Tumor Imaging, FDG-PET, Computed Tomography (CT), Biospecimen Collection, Biological Sample Collection, ClonoSeq Assay, ClonoSeq, Bone Marrow Biopsy, Biopsy of Bone Marrow
C. Babis Andreadis, Eli Lilly and Company, Genentech, Inc., Adaptive Biotechnologies
Mantle Cell Lymphoma
07/28
07/28
 

Download Options